• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1281699 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type: \6 l! {9 U6 |( y. S1 q$ B( E: D2 X. l
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
  j. M' X& q6 A% j: S5 u# U& Z+ Author Affiliations1 Z6 b  A0 t, J8 p9 b% [5 G

9 |  p: ]# O; _$ q' A1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan # }4 z' h* `. Y2 x
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; I6 q" ~' p% _+ b% F& ^0 R" O$ {8 I3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' s+ m$ @5 p9 L) D+ H4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
% }  l  ?: y! }- N: }& A" l5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & j. Y8 P+ H+ ~; x
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( H7 ~7 e/ b- g% {+ M6 G, H7Kinki University School of Medicine, Osaka 589-8511, Japan
8 {3 H! i* |' J. r) S8Izumi Municipal Hospital, Osaka 594-0071, Japan & d; M" v+ q  h% l4 N" i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ) N$ J: D: y( N% y$ r) A
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 b7 J8 L2 Q" A3 HAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
8 J/ O2 C% I9 @. o7 U2 [: K) l! t
" y2 d1 C6 H) i  R9 O$ s
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
6 T6 ]. Q5 M, D6 x3 r! e& X8 p  P. G# P5 S4 T  P4 I+ a4 ^
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
! ?/ g4 s: ^2 v: n7 D% E& q
" y& T& V! x2 v0 [1 GAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
3 @8 k2 m' e( ^+ v9 y1 z5 G) h" S3 w7 o% F8 t4 |
Published online on: Thursday, December 1, 2011
9 e7 K1 ^# j" K  y% y7 [: v! k1 O; r5 U/ M
Doi: 10.3892/ol.2011.507 3 c) k4 V& [" M0 B- [
$ }7 i$ m& ^+ O) ]5 ?. ]. d. H
Pages: 405-410 7 y  ?% F4 w6 E  F

: w1 {/ R: L3 ^9 h5 F) NAbstract:, a* c) B" u$ b' v+ }$ A9 n; s
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.3 }- f& _/ S3 K" C

( Q( u" X) i) l) E; K% B  _( l$ w
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
) W( P9 m+ L! F& p5 Z( @. ]4 LF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
* z; H  Y, A# \  f0 ]" n. G4 K0 g1 o+ Author Affiliations, E6 ?( Y. e# F- y1 R4 V0 s/ a
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 4 `' S3 g  R# K& C5 g
2Department of Thoracic Surgery, Kyoto University, Kyoto . I9 j. L+ J* r
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
& `* d, |, m' V! h&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
* u5 e& r# K. q( g; hReceived September 3, 2010. / ]9 x5 m+ u9 P7 t
Revision received November 11, 2010. + _6 v. E2 ^6 x5 r! i! }# o8 L& y
Accepted November 17, 2010. " U9 d8 _: D3 V% |0 Z( u
Abstract
" y8 e5 ~. D- E& A0 s% d  mBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
9 D( ~& l* t- B- vPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
2 Q' i& n9 F5 H+ g! GResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
3 [: F2 V( K- H' \) ~( u! ?! O1 U- BConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 8 C7 r+ J* l# T! |, N1 T9 M0 g- U
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。9 k: ?0 y4 Q5 [/ ~5 B* e
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?' W. \0 ]7 l7 s' R. G
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy- ~6 n1 ~6 i1 ]5 D7 u, R9 N
http://clinicaltrials.gov/ct2/show/NCT01523587
8 L8 m  x0 z/ a. O3 i1 v9 z& F
* P* u( w$ D+ kBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
; ~* A8 X& S  S. f* r; \7 ehttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
  V5 J' ?, `0 T# x4 D
3 r8 P/ Q+ I* o; R从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
  _0 L7 H, n+ z$ s1 o, A( g至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
, l' r2 m& T( I2 I" v
没有副作用是第一追求,效果显著是第二追求。
& ]+ v, [( O  E. Y  C* O7 p不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表